| Bioactivity | DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1R/5R=389/630 μM) and III receptors (IC50: mGlu4R/6R/7R/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects[1][2]. |
| Invitro | DCG-IV is also an NMDA receptor agonist in the rat cortical slice[3]. |
| In Vivo | DCG-IV (1-10 mg/kg; i.p.) depresses the phencyclidine (PCP)-induced hyperlocomotion[4]. Animal Model: |
| Name | DCG-IV |
| CAS | 147782-19-2 |
| Formula | C7H9NO6 |
| Molar Mass | 203.15 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Brabet I, et al. Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all clonedmetabotropic glutamate receptor subtypes. Neuropharmacology. 1998 Aug;37(8):1043-51. [2]. Bertrand HO, et al. Common and selective molecular determinants involved in metabotopic glutamate receptoragonist activity. J Med Chem. 2002 Jul 18;45(15):3171-83. [3]. Uyama Y, et al. DCG-IV, a potent metabotropic glutamate receptor agonist, as an NMDA receptor agonist in the rat cortical slice. Brain Res. 1997 Mar 28;752(1-2):327-30. [4]. Tomita N, et al. The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice. Ann N Y Acad Sci. 2000 Sep;914:284-91. |